Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
AYTU BIOPHARMA, INC amended revolving credit of Increase of $2,000,000 to revolving loan commitment, resulting in aggregate revolving facility size of $14,500,000 with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and the lenders party thereto at Not specified maturing Not specified.
- Instrument
- revolving credit
- Principal
- Increase of $2,000,000 to revolving loan commitment, resulting in aggregate revolving facility size of $14,500,000
- Counterparty
- Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and the lenders party thereto
- Rate
- Not specified
- Maturity
- Not specified
- Event
- amendment
Exact text from the filing
and the lenders party thereto (agent and such lenders, collectively, the “ Eclipse Lender ”). The Eclipse Amendment, among other things, provided for an aggregate increase of $2,000,000 to the Eclipse Lender’s commitment to make revolving loans from time to time to the Neos Obligors, resulting in an aggregate revolving facility size of $14,500,000 (such facility,
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
AYTU BIOPHARMA, INC amended credit facility of No change in principal amount; amendment permitted the increase in revolving loan commitment under the Eclipse Facility with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders, and Avenue Capital Management II, L.P. as administrative agent at Not specified maturing Not specified.
- Instrument
- credit facility
- Principal
- No change in principal amount; amendment permitted the increase in revolving loan commitment under the Eclipse Facility
- Counterparty
- Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders, and Avenue Capital Management II, L.P. as administrative agent
- Rate
- Not specified
- Maturity
- Not specified
- Event
- amendment
Exact text from the filing
In connection with the Eclipse Amendment, on March 24, 2023, the Obligors entered into the Second Amendment to Loan Documents (the “ Avenue Amendment ”) amending that certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022, the “ Avenue Agreement ”), by and among the Obligors, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P., as lenders (the “ Avenue Capital Lenders ”), and Avenue Capital Management II, L.P., as administrative agent (the “ Avenue Capital Agent ”). The Avenue Amendment, among other things, permitted the increase in revolving loan commitment provided by the Eclipse Lender under the Eclipse Facility as provided for in the Eclipse Amendment.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AYTU BIOPHARMA, INC amended Avenue Amendment with Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P. (effective 2023-03-24).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P.
- Effective
- 2023-03-24
Exact text from the filing
In connection with the Eclipse Amendment, on March 24, 2023, the Obligors entered into the Second Amendment to Loan Documents (the “ Avenue Amendment ”) amending that certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022, the “ Avenue Agreement ”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AYTU BIOPHARMA, INC amended Eclipse Amendment with Eclipse Business Capital LLC, as agent, and the lenders party thereto valued at aggregate increase of $2,000,000 (effective 2023-03-24).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Eclipse Business Capital LLC, as agent, and the lenders party thereto
- Value
- aggregate increase of $2,000,000
- Effective
- 2023-03-24
Exact text from the filing
On March 24, 2023, Aytu BioPharma, Inc. (“ Aytu ” or the “ Company ”) entered into an Amendment No. 4 (the “ Eclipse Amendment ”) to Loan and Security Agreement dated October 2, 2019
View on SEC.gov